Drug Trial Radar · NCT04259164
Anti-inflammatory Effects Glycopyrronium
Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Sep 10, 2020
Primary completion
Dec 29, 2022
Study completion Dec 29, 2022
Sponsor
- Lead sponsor
- University Medical Center GroningenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Feb 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-blind, randomized, two-way cross-over study with two treatment periods. 28 subjects with asthma will be randomized in 1:1 ratio to treatment A) Indacaterol/Mometasone 150/160 μg once daily and treatment B) Indacaterol/Glycopyrronium/Mometasone 150/50/80 μg once daily for period 1. For period 2, subjects will be crossed over to the other treatment arm. Subjects will be screened during the first visit. After inclusion subjects will be seen for 3 visits during the Run-in period, 3 visits during treatment period 1 and 3 visits during treatment period 2. During these visits patients will be clinically characterized and exposed to allergen challenge tests.
Conditions
- Asthma
- Allergic Asthma
Interventions
QVM149Drug
Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
QMF149Drug
Mometasone / Indacaterol
Primary outcomes
What the sponsor says the trial is designed to measure.
- % of sputum eosinophilsTime frame: 24 hours after allergen challenge at the end of each treatment period vs. control allergen challenge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Medical Center Groningen
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.